<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02883712</url>
  </required_header>
  <id_info>
    <org_study_id>2011_37</org_study_id>
    <secondary_id>2012-A00916-37</secondary_id>
    <nct_id>NCT02883712</nct_id>
  </id_info>
  <brief_title>Study of Predictors of Response to Anti Epilepsy in Epilepsy</brief_title>
  <acronym>RESISTANT</acronym>
  <official_title>Study of Predictors of Response to Anti Epilepsy in Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pharmacoresistant epilepsy remains around 30% despite the development of 25 anti epileptic&#xD;
      drugs. Of course, this can be explained by pharmacoresistant epileptic brain diseases, as&#xD;
      exemplified by some genetic diseases. However, the lack of specific guidelines for the choice&#xD;
      of the anti epileptic drugs (apart from generalized and partial epilepsy) and the very large&#xD;
      number of drugs with different and sometimes complex metabolism are challenges for&#xD;
      neurologists. Among the 30 % of pharmacoresistant epilepsy, there is a part related to&#xD;
      pharmacokinetic drawbacks that could be overcome with a more rigorous approach (i.e. dosage&#xD;
      and pharmacogenetics tools). Moreover, the new anti epileptic drugs have metabolism more&#xD;
      unrelated with the cytochrome P450 and less generalised adverse events. However, their&#xD;
      metabolism could be more complexe (i.e. the less known Uridine&#xD;
      5'-diphospho-glucuronyltransferase (UGT) pathway) and bring more insidious neurological&#xD;
      adverse events (i.e. depression, anxiety exacerbation, cognitive disorders worsening) which&#xD;
      could largely impede the observance and the quality of life even if the number of seizure is&#xD;
      reduced or not. The goal is to determine the predictive and the modulating factors of&#xD;
      pharmacoresistance with a global analysis (i.e. whatever the anti epileptic drugs) and with a&#xD;
      specific analysis (drug by drug) from a cohort of 1000 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal is to determine the predictive and the modulating factors of pharmacoresistance with&#xD;
      a global analysis (i.e. whatever the anti epileptic drugs) and with a specific analysis (drug&#xD;
      by drug with their specific metabolism pathways) from a cohort of 1000 patients. The response&#xD;
      to the antiepileptic drugs modification will be analyse 3 months after the modification, with&#xD;
      the analysis of the number of seizures, the quality of life, the Clinical Global Impression,&#xD;
      the adverse events, the systematic dosage of all the molecules (residual concentration just&#xD;
      before the taken) and the pharmacogenetic analysis of the main metabolism pathways and the&#xD;
      main pharmacodynamic targets.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    defect inclusion&#xD;
  </why_stopped>
  <start_date type="Actual">May 21, 2013</start_date>
  <completion_date type="Actual">January 2021</completion_date>
  <primary_completion_date type="Actual">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical global impression of the patient</measure>
    <time_frame>3 months</time_frame>
    <description>Clinical global impression assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of seizure</measure>
    <time_frame>3 months</time_frame>
    <description>recorded on the agenda of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 months</time_frame>
    <description>Analyse with the Quality Of Life In Epilepsy Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>reported by the patients with a particular attention to attention and concentration worsening on interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of the anti epileptic drug</measure>
    <time_frame>3 months</time_frame>
    <description>plasmatic drug concentration will be systematically</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetics of the uridine 5'-diphosphate glucuronosyltransférases (UGT1A1, UGT2B7, UGT1A4)</measure>
    <time_frame>3 months</time_frame>
    <description>the metabolism pathways of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenetics of the Cytochrome P450 (2D6, 2C9, 2C19)</measure>
    <time_frame>3 months</time_frame>
    <description>the metabolism pathways of the drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression inventory for epilepsy</measure>
    <time_frame>3 months</time_frame>
    <description>Neurological Disorders Depression Inventory for Epilepsy</description>
  </secondary_outcome>
  <enrollment type="Actual">155</enrollment>
  <condition>Seizure</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasmatic and serum samples for the dosage of the drugs Leucocytes for the intracellular&#xD;
      dosage of the drugs DNA for pharmacogenetics analysis of the metabolism and pharmacodynamic&#xD;
      targets of the drugs DNA for the genetic causes of epilepsy&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Consecutive patients referred to our center with epilepsy (pharmacoresistant or&#xD;
        pharmacosensitive)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Epileptic patients who required a treatment adaptation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients unable to give reliable information and without caregiver&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  Severe comorbidity, which would impede interpretation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David DEVOS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2016</study_first_posted>
  <last_update_submitted>March 9, 2021</last_update_submitted>
  <last_update_submitted_qc>March 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epilepsy</keyword>
  <keyword>pharmacoresistant</keyword>
  <keyword>antiepileptic drug</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>pharmacodynamic</keyword>
  <keyword>pharmacogenetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

